Haemanthus, a new health tech company founded by Elizabeth Holmes’ partner Billy Evans, focuses on laser-based diagnostics and emphasizes Holmes plays no role.
Author: Aino Lehtinen
Aino Lehtinen
Aino Lehtinen is a Finnish journalist and editor originally from Helsinki, Finland. She studied Media and Communication Studies at the University of Tampere, where she developed a strong interest in investigative storytelling and cross-border journalism. After several years working with leading Finnish publications, she relocated to Berlin, Germany, where she currently lives and works as a freelance editor. Lehtinen focuses on issues such as digital privacy, press freedom, and the intersection of media and politics in Europe. Fluent in Finnish, English, and German, she often collaborates with international media outlets on transnational reporting projects.
Biopharma startup will channel the funds into clinical development of AVA-NP-695 and expansion of its IP assets.
San Francisco-based Omada Health has filed to go public on the Nasdaq under the ticker “OMDA”, joining a small group of healthtech firms targeting public listings in 2025.
NewLimit, co-founded by Coinbase’s Brian Armstrong, will use the new funding to advance AI-guided anti-aging drug development.
The artist has secured a multi-album agreement with Warner Records and is transferring his publishing rights to the Merrit Group, led by Cameron Strang.
Biotech-beauty brand EGA has achieved full retail distribution across South Korea just nine months after its launch, marking a notable move in the anti-aging segment.
Grammy-winning artist Justin Timberlake will take the stage at ITU Stadium on July 30 as part of his 2025 world tour. Tickets go on sale May 8.
Switzerland-based health technology company Hilo secures $42 million in Series B funding to accelerate global expansion and product development.
Japanese startup Craif raises $22 million to expand its non-invasive early cancer detection technology and strengthen R&D efforts in the United States.
Vertex Pharmaceuticals CEO Reshma Kewalramani, originally from Mumbai, has been included in TIME Magazine’s 2025 list of the 100 most influential people.